Leveraging Innovative Technology to Treat COVID-19 Patients

10:30 AM - 11:45 AM (PDT), Monday, June 8, 2020
Search General Info
Search Education
Search Partnering Companies
As the consequences of COVID-19 infection have been felt around the world, companies moved swiftly to test many of the products in their pipelines against SARS CoV2, the virus that causes COVID-19, as well as the complex set of complications associated with the virus. This has led to a broad array of novel approaches to treating patients infected with the virus, from antibodies that could be given as prevention or treatment to products that help reduce the impact of the cytokine storm and treat Acute Respiratory Distress Syndrome (ARDS), severe inflammation, and secondary bacterial infections. This panel of top scientists and industry leaders will share information on the development of these vital treatment options and how partnerships between industry, governments and NGOs will help speed the availability of new medicines that benefit patients.
Moderator
photo
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization
Speakers
photo
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization
photo
President, Plasma-Derived Therapeutics Business Unit
Takeda
photo
Chief Executive Officer and Director
Vir Biotechnology, Inc.
photo
President & CEO
SAB Biotherapeutics
photo
Founder, Chairman and CEO
Athersys, Inc.
George Yancopoulos
Co-Founder, President & Chief Scientific Officer
Regeneron